Pharmaceutical giants Merck & Co Inc (NYSE:MRK) and Pfizer Inc (NYSE:PFE) today reported second-quarter results. While the former beat top- and bottom-line estimates thanks in part to cancer drug Keytruda sales, it also issued a dismal annual profit outlook. Pfizer beat earnings and revenue expectations as well, but lifted its guidance for the full year.  Merck stock is down 6.2% to trade at $119.89 at last check, gapping below the $120 level that contained June and March pullbacks. Shares are also on track ...